Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%

MT Newswires Live

昨天

Amplia Therapeutics (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.

The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.

The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.

Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining "increasing attention" as a drug target in solid tumors, the filing added.

Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.

The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2621255987"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621255987\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621255987?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621255987","market":"hk","top_or_hot":-1,"title":"Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.</p><p>The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.</p><p>The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.</p><p>Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.</p><p>Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.</p><p>The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Reports 11.1-Month Median Survival, Five Complete Responses in Pancreatic Cancer Trial, Shares Surge 82%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-23 10:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.</p><p>The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.</p><p>The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.</p><p>Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.</p><p>Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.</p><p>The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2621255987","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621255987","pubTimestamp":1774233784,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research  in San Diego in April.The company's shares surged past 82% to reach their h","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4139":"生物科技"},"translate_title":"Amplia Therapeutics报告中位生存期为11.1个月，胰腺癌试验中有5项完全缓解，股价飙升82%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) said mature data from its ongoing ACCENT clinical trial in advanced pancreatic cancer showed a median overall survival of 11.1 months and five complete responses to date, with its lead drug candidate narmafotinib combined with chemotherapy, according to a Monday Australian bourse filing.The company said five patients have achieved a complete response in the Phase 1b/2a trial, resulting in a complete response rate of 7.8%.The median overall survival of 11.1 months represents a two-month improvement compared to chemotherapy alone, with no additional toxicity burden, the filing added.Narmafotinib is the company's inhibitor of the protein FAK, which is overexpressed in pancreatic cancer and is gaining \"increasing attention\" as a drug target in solid tumors, the filing added.Amplia said it has been chosen to present trial data at the annual meeting of the American Association of Cancer Research (AACR) in San Diego in April.The company's shares surged past 82% to reach their highest price since August 2025 in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}